Contracts › 75N93025C00035
75N93025C00035: Advance a Novel Therapeutic to a First-In-Human Clinical Study
Awarded to Locus Biosciences Inc by National Institutes of Health (NIH).
$7.9Mobligated
$27.8Mpotential value
07 February 2029current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93025C00035 |
|---|---|
| Awardee | Locus Biosciences Inc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | NC |
| Offers received | 16 |
| Period of performance | 24 September 2025 to 07 February 2029 |
| Potential end | 07 February 2029 |
| Estimated recompete solicitation | ~Q3 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record